<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697203</url>
  </required_header>
  <id_info>
    <org_study_id>NC18589</org_study_id>
    <nct_id>NCT00697203</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)</brief_title>
  <official_title>A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This 4 arm study will evaluate the efficacy and safety of RO4607381 when co-administered with
      pravastatin in patients with low or relatively low HDL-C levels. Patients will be randomised
      to one of 4 groups to receive either RO4607381 300mg, 600mg or 900mg po daily, or placebo po
      daily, for 12 weeks.All patients will also receive pravastatin 40mg po daily for 12 weeks.The
      anticipated time on study treatment is 3 months and the target sample size is 100-500
      individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in HDL-C Level\n</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in HDL-C Level\n</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in: Total Cholesterol, Triglycerides, HDL-C, LDL-C, HDL-2, HDL-3, ApoA1, ApoA2, ApoB, LpAI</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Fasting Glucose Level</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs, Lab Parameters, Vital Signs, ECG</measure>
    <time_frame>Through 9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratios of Total HDL-C/LDL-C, HDL-2/HDL-3, ApoA1/ApoB</measure>
    <time_frame>Baseline and at 12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">292</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Dalcetrapib 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dalcetrapib 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dalcetrapib 900mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>po daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>40mg po daily for 12 weeks</description>
    <arm_group_label>Dalcetrapib 300mg</arm_group_label>
    <arm_group_label>Dalcetrapib 600mg</arm_group_label>
    <arm_group_label>Dalcetrapib 900mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalcetrapib</intervention_name>
    <description>300mg po daily for 12 weeks</description>
    <arm_group_label>Dalcetrapib 300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalcetrapib</intervention_name>
    <description>600mg po daily for 12 weeks</description>
    <arm_group_label>Dalcetrapib 600mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalcetrapib</intervention_name>
    <description>900mg po daily for 12 weeks</description>
    <arm_group_label>Dalcetrapib 900mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients 18-75 years of age;

          -  dyslipidemic patients with low or relatively low HDL-C levels during treatment with
             pravastatin.

        Exclusion Criteria:

          -  women who are pregnant, breastfeeding, or of child-bearing potential;

          -  morbid obesity;

          -  uncontrolled hypertension;

          -  poorly controlled or insulin-treated diabetes;

          -  high creatinine levels or history of statin-associated myopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610-4319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chalmette</city>
        <state>Louisiana</state>
        <zip>70043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springdale</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warminster</city>
        <state>Pennsylvania</state>
        <zip>18974</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <results_first_submitted>July 17, 2019</results_first_submitted>
  <results_first_submitted_qc>December 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2020</results_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Dalcetrapib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dalcetrapib 300mg</title>
          <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 300mg po daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Dalcetrapib 600mg</title>
          <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 600mg po daily for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Dalcetrapib 900mg</title>
          <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 900mg po daily for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo: po daily for 12 weeks
Pravastatin: 40mg po daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dalcetrapib 300mg</title>
          <description>Pravastatin: 40mg po daily for 12 weeks
dalcetrapib: 300mg po daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Dalcetrapib 600mg</title>
          <description>Pravastatin: 40mg po daily for 12 weeks
dalcetrapib: 600mg po daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Dalcetrapib 900mg</title>
          <description>Pravastatin: 40mg po daily for 12 weeks
dalcetrapib: 900mg po daily for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo: po daily for 12 weeks
Pravastatin: 40mg po daily for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="74"/>
            <count group_id="B4" value="74"/>
            <count group_id="B5" value="292"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="10.24"/>
                    <measurement group_id="B2" value="57.1" spread="10.53"/>
                    <measurement group_id="B3" value="56.7" spread="10.52"/>
                    <measurement group_id="B4" value="57.2" spread="10.87"/>
                    <measurement group_id="B5" value="56.7" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in HDL-C Level\n</title>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib 300mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 300mg po daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dalcetrapib 600mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 600mg po daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Dalcetrapib 900mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 900mg po daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: po daily for 12 weeks
Pravastatin: 40mg po daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in HDL-C Level\n</title>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.18" spread="2.19"/>
                    <measurement group_id="O2" value="31.42" spread="2.29"/>
                    <measurement group_id="O3" value="36.45" spread="2.24"/>
                    <measurement group_id="O4" value="2.31" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in HDL-C Level\n</title>
        <time_frame>12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib 300mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 300mg po daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dalcetrapib 600mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 600mg po daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Dalcetrapib 900mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 900mg po daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: po daily for 12 weeks
Pravastatin: 40mg po daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in HDL-C Level\n</title>
          <units>Percent change in mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.58" spread="0.84"/>
                    <measurement group_id="O2" value="11.90" spread="0.88"/>
                    <measurement group_id="O3" value="13.92" spread="0.86"/>
                    <measurement group_id="O4" value="0.73" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in: Total Cholesterol, Triglycerides, HDL-C, LDL-C, HDL-2, HDL-3, ApoA1, ApoA2, ApoB, LpAI</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib 300mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 300mg po daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dalcetrapib 600mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 600mg po daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Dalcetrapib 900mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 900mg po daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: po daily for 12 weeks
Pravastatin: 40mg po daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in: Total Cholesterol, Triglycerides, HDL-C, LDL-C, HDL-2, HDL-3, ApoA1, ApoA2, ApoB, LpAI</title>
          <units>Percent change in mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.08" spread="1.45"/>
                    <measurement group_id="O2" value="12.58" spread="1.52"/>
                    <measurement group_id="O3" value="9.36" spread="1.48"/>
                    <measurement group_id="O4" value="1.35" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.95" spread="3.93"/>
                    <measurement group_id="O2" value="4.45" spread="4.11"/>
                    <measurement group_id="O3" value="-5.01" spread="4.02"/>
                    <measurement group_id="O4" value="-4.25" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.18" spread="2.19"/>
                    <measurement group_id="O2" value="31.42" spread="2.29"/>
                    <measurement group_id="O3" value="36.45" spread="2.24"/>
                    <measurement group_id="O4" value="2.31" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.51" spread="2.58"/>
                    <measurement group_id="O2" value="10.88" spread="2.73"/>
                    <measurement group_id="O3" value="5.28" spread="2.65"/>
                    <measurement group_id="O4" value="3.84" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.10" spread="8.19"/>
                    <measurement group_id="O2" value="97.40" spread="8.82"/>
                    <measurement group_id="O3" value="121.2" spread="8.49"/>
                    <measurement group_id="O4" value="10.54" spread="8.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.95" spread="1.96"/>
                    <measurement group_id="O2" value="20.94" spread="2.11"/>
                    <measurement group_id="O3" value="23.56" spread="2.03"/>
                    <measurement group_id="O4" value="0.68" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoA1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.03" spread="1.39"/>
                    <measurement group_id="O2" value="13.60" spread="1.44"/>
                    <measurement group_id="O3" value="14.90" spread="1.40"/>
                    <measurement group_id="O4" value="1.01" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoA2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="1.23"/>
                    <measurement group_id="O2" value="8.07" spread="1.33"/>
                    <measurement group_id="O3" value="8.36" spread="1.28"/>
                    <measurement group_id="O4" value="0.72" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="1.90"/>
                    <measurement group_id="O2" value="4.62" spread="2.01"/>
                    <measurement group_id="O3" value="-1.64" spread="1.95"/>
                    <measurement group_id="O4" value="-0.71" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LpA1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.06" spread="3.59"/>
                    <measurement group_id="O2" value="22.68" spread="3.59"/>
                    <measurement group_id="O3" value="24.76" spread="3.40"/>
                    <measurement group_id="O4" value="3.32" spread="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Fasting Glucose Level</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib 300mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 300mg po daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dalcetrapib 600mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 600mg po daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Dalcetrapib 900mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 900mg po daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: po daily for 12 weeks
Pravastatin: 40mg po daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Fasting Glucose Level</title>
          <units>Percent change in mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="1.69"/>
                    <measurement group_id="O2" value="6.03" spread="1.79"/>
                    <measurement group_id="O3" value="5.42" spread="1.72"/>
                    <measurement group_id="O4" value="3.00" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AEs, Lab Parameters, Vital Signs, ECG</title>
        <time_frame>Through 9 Months</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib 300mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 300mg po daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dalcetrapib 600mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 600mg po daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Dalcetrapib 900mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 900mg po daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: po daily for 12 weeks
Pravastatin: 40mg po daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>AEs, Lab Parameters, Vital Signs, ECG</title>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratios of Total HDL-C/LDL-C, HDL-2/HDL-3, ApoA1/ApoB</title>
        <time_frame>Baseline and at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib 300mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 300mg po daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dalcetrapib 600mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 600mg po daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Dalcetrapib 900mg</title>
            <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 900mg po daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: po daily for 12 weeks
Pravastatin: 40mg po daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Ratios of Total HDL-C/LDL-C, HDL-2/HDL-3, ApoA1/ApoB</title>
          <units>Percent Change in Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL-C/LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.76" spread="2.96"/>
                    <measurement group_id="O2" value="-16.0" spread="3.20"/>
                    <measurement group_id="O3" value="-19.4" spread="3.04"/>
                    <measurement group_id="O4" value="3.09" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB/ApoA1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.97" spread="2.10"/>
                    <measurement group_id="O2" value="-5.79" spread="2.19"/>
                    <measurement group_id="O3" value="-12.7" spread="2.11"/>
                    <measurement group_id="O4" value="-1.84" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-2/HDL-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.18" spread="5.88"/>
                    <measurement group_id="O2" value="63.40" spread="6.33"/>
                    <measurement group_id="O3" value="76.38" spread="6.10"/>
                    <measurement group_id="O4" value="8.89" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dalcetrapib 300mg</title>
          <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 300mg po daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Dalcetrapib 600mg</title>
          <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 600mg po daily for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Dalcetrapib 900mg</title>
          <description>Pravastatin: 40mg po daily for 12 weeks
Dalcetrapib: 900mg po daily for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo: po daily for 12 weeks
Pravastatin: 40mg po daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Muscle Tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ryan Black</name_or_title>
      <organization>DalCor Pharmaceuticals</organization>
      <email>rblack@dalcorpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

